top of page

Antheia CEO on How Biomanufacturing can De-Risk Pharmaceutical Production

Updated: Jan 9

In a recent Q&A with European Pharmaceutical Manufacturer Antheia CEO and co-founder Dr. Christina Smolke discussed how latency and variability within agricultural supply chains remains the number one challenge in the pharmaceutical-grade production of plant-based ingredients today. Underscoring the benefits of biomanufacturing in addressing these challenges, Dr. Smolke describes fermentation-based production as “agile and flexible, so the industry can respond to different events – be they geopolitical or environmental – addressing the latency challenge directly, or circumventing it entirely in the controlled environment of a bioreactor.” The controlled methodology, she said, yields more consistency which is essential within the demanding framework of pharma.

Read the full text of the interview Q&A here.

bottom of page